Recombinant Mouse GPC3/Glypican 3 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00001P-500UG
Mouse GPC3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Mouse GPC3/Glypican 3 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00001P-500UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Mouse GPC3/Glypican 3 Protein is expressed from HEK293 with His tag at the C-terminus.It contains Gln25-Met557. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q8CFZ4 |
Target Symbol | GPC3/Glypican 3 |
Species | Mouse |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Gln25-Met557 |
Mol. Weight | The protein has a predicted MW of 61.62 kDa. Due to furin-like convertase cleavage site and glycosylation, the protein migrates to 32-42 kDa and 75-85 kDa based on Tris-Bis PAGE result. |
Form | Liquid |
Formulation | Supplied as 0.22 um filtered solution in PBS (pH 7.4). |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Mouse GPC3, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Anti-GPC3 Antibody, hFc Tag with the EC50 of 6.6ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Shipping | Shipped with dry ice. |
Gene Background | Glypican-3 is a protein ,which is encoded by the GPC3 gene in humans.The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa.Glypican 3 is a potential therapeutic target for treating liver cancer and other cancers. Several therapeutic anti-GPC3 antibodies have been developed. |